Underwriters therefore need to continue to review and assess medical evidence for any associated side effects and potential comorbidities, including cardiovascular status, renal and hepatic function, and mental health or cognitive concerns
Together, these findings highlight that while ACE-inhibitory peptides remain the most extensively studied, peptide-based strategies in cardiovascular diseases potentially extend beyond blood pressure regulation to include vascular repair, plaque stabilization, and endothelial modulation
This can result in health issues such as weakened immunity, skin complications, digestion issues, impaired bone development, and neurological disorders
Finding and maintaining the right dose of semaglutide or tirzepatide during this phase can support long-term success and help reduce the risk of weight regain